Clinical Trials Logo

Clinical Trial Summary

To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone (BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.


Clinical Trial Description

This will be a single center, open-labeled, single arm, phase-II pilot study. The treatment and the response evaluation phase will last from the time of enrollment up to 21 months (evaluation will be carried out every 3 months in the first 9 months and every 6 months from Month 9 to Month 21). The maintenance and follow-up phase to assess for progression of disease will last from 21 months to 45 months after enrollment (evaluation will be carried out every 12 months). The total study duration will be 4 years after the last patient starts study medication. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03982771
Study type Interventional
Source Peking Union Medical College Hospital
Contact
Status Recruiting
Phase Phase 2
Start date January 1, 2019
Completion date January 1, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05995834 - Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)
Terminated NCT04838860 - Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease Phase 2
Recruiting NCT04743687 - Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial Phase 2
Recruiting NCT05345522 - A Study of Anti-IL-6R mAb Injection in Patients With iMCD Phase 2